REG - Argent Biopharma Ltd - Placing to Raise A$200,000

Argent BioPharmaAnnouncement

24/10/2024 07:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241024:nRSX4447Ja&default-theme=true

RNS Number : 4447J  Argent Biopharma Limited  24 October 2024

 

24 October 2024

 

Argent BioPharma Ltd.

(Argent BioPharma or the Company)

 

Placing to Raise A$200,000

Argent BioPharma, an innovative multidisciplinary drug development company
within the biopharmaceutical sector, announces that it has received firm
commitments from a professional and sophisticated investor to raise A$200,000
(Placement) through the issue of 666,667 fully paid ordinary shares at A$0.30
per share (Placement Shares).

Proceeds from the Placement will support the continuation of the Company's
drug development pipeline, including CannEpil® and CimetrA® in the US and EU
markets and general working capital purposes.

The Placement Shares are to be issued under the Company's existing placement
capacity in accordance with ASX listing Rule 7.1.

-Ends-

 

Authorised for release by the board of directors, for further information
please contact:

 

 Argent BioPharma                                             Argent BioPharma

 Roby Zomer                                                   Rowan Harland

 CEO & Managing Director                                      Company Secretary

 +61 8 6555 2950                                              +61 8 6555 2950

 info@argentbiopharma.com (mailto:info@argentbiopharma.com)   info@argentbiopharma.co (mailto:info@argentbiopharma.co.uk) m

 

About Argent BioPharma

 

Argent BioPharma Limited (the "Company") (ASX: RGT; LSE: RGT; OTCQB: RGTLF) an
innovative multidisciplinary drug development Company within the
biopharmaceutical sector.  The Company focuses on multidisciplinary methods
with Nanotechnology, developing multi-target therapies for comprehensive
disease management, especially concerning the Central nervous system ("CNS")
and Immunology treatments.

 

Follow us through our social media channels:

LinkedIn: Argent BioPharma

Twitter: @ArgentBioPharma

Facebook: Argent BioPharma

Total voting rights

On issue of the Fundraising Shares, the Company will have 54,272,269 Ordinary
Shares in issue, each with one voting right. Therefore, the Company's total
number of Ordinary Shares in issue and voting rights will be 54,272,269 and
this figure may be used by shareholders from issue of the Placing Shares as
the denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, the
Company under the FCA's Disclosure Guidance and Transparency Rules.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEGUBDGUDDDGSS